Table 5.
Univariate and BioScore-adjusted Associations of Clinicopathologic Features and Algorithms With RCC-specific Death for 634 Patients With ccRCC
| Feature | Univariate* | BioScore-adjusted* | ||
|---|---|---|---|---|
| HR (95% CI) | c Index | HR (95% CI) | c Index | |
| Age at surgery, y | ||||
| <65 | 1.0 | 1.0 | ||
| ≥65 | 0.97 (0.74–1.28) | 0.502 | 0.80 (0.61–1.06) | 0.692 |
| Sex | ||||
| Women | 1.0 | 1.0 | ||
| Men | 1.18 (0.88–1.58) | 0.510 | 1.16 (0.87–1.55) | 0.701 |
| Symptoms | ||||
| Absent | 1.0 | 1.0 | ||
| Present | 2.55 (1.83–3.57) | 0.595 | 2.01 (1.43–2.82) | 0.722 |
| Constitutional symptoms | ||||
| Absent | 1.0 | 1.0 | ||
| Present | 2.74 (2.08–3.60) | 0.614 | 2.12 (1.60–2.81) | 0.726 |
| ECOG performance status | ||||
| 0 | 1.0 | 1.0 | ||
| ≥1 | 0.91 (0.56–1.50) | 0.502 | 0.95 (0.58–1.57) | 0.695 |
| Primary tumor classification | ||||
| pT1a | 1.0 | 1.0 | ||
| pT1b | 4.71 (2.20–10.09) | 3.91 (1.82–8.40) | ||
| pT2 | 11.09 (5.22–23.56) | 10.74 (5.05–22.85) | ||
| pT3a | 18.22 (8.47–39.17) | 13.02 (6.01–28.21) | ||
| pT3b, pT3c, and pT4 | 23.83 (11.52–49.28) | 0.759 | 15.57 (7.45–32.52) | 0.800 |
| Regional lymph node involvement | ||||
| pNX and pN0 | 1.0 | 1.0 | ||
| pN1 and pN2 | 4.72 (3.00–7.43) | 0.546 | 3.65 (2.30–5.78) | 0.700 |
| Distant metastases | ||||
| pM0 | 1.0 | 1.0 | ||
| pM1 | 7.99 (5.90–10.81) | 0.639 | 6.04 (4.41–8.27) | 0.750 |
| TNM stage groupings | ||||
| I | 1.0 | 1.0 | ||
| II | 3.06 (1.84–5.10) | 3.43 (2.06–5.73) | ||
| III | 7.34 (4.94–10.90) | 5.58 (3.72–8.35) | ||
| IV | 20.17 (13.41–30.34) | 0.791 | 16.21 (10.65–24.66) | 0.816 |
| Tumor size, cm | ||||
| <5 | 1.0 | 1.0 | ||
| ≥5 | 5.43 (3.52–8.38) | 0.645 | 4.48 (2.89–6.93) | 0.746 |
| Nuclear grade | ||||
| 1 and 2 | 1.0 | 1.0 | ||
| 3 | 7.22 (4.96–10.52) | 5.83 (3.95–8.61) | ||
| 4 | 21.14 (13.55–32.97) | 0.768 | 11.96 (7.27–19.67) | 0.792 |
| Coagulative tumor necrosis | ||||
| Absent | 1.0 | 1.0 | ||
| Present | 7.22 (5.42–9.61) | 0.737 | 5.02 (3.66–6.88) | 0.769 |
| UISS | ||||
| I | 1.0 | 1.0 | ||
| II | 9.52 (5.26–17.24) | 7.94 (4.37–14.44) | ||
| III | 18.21 (8.02–41.33) | 16.91 (7.43–38.45) | ||
| IV and V | 51.96 (27.84–96.96) | 0.774 | 35.76 (18.89–67.69) | 0.819 |
| SSIGN score | ||||
| Low, 0–2 | 1.0 | 1.0 | ||
| Intermediate, 3–6 | 5.59 (3.31–9.44) | 5.34 (3.16–9.03) | ||
| High, 7+ | 30.61 (18.58–50.41) | 0.821 | 22.55 (13.39–37.97) | 0.837 |
RCC indicates renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; HR, hazard ratio; CI, confidence interval; c, concordance; ECOG, Eastern Cooperative Oncology Group; UISS, UCLA Integrated Scoring System; SSIGN, Mayo Clinic stage, size, grade, and necrosis.
*
All P values <.001 except for age (univariate P =.84; BioScore-adjusted P =.12); sex (univariate P=.26; BioScore-adjusted P=.32); and ECOG performance status (univariate P =.72; BioScore-adjusted P =.85).